Literature DB >> 22824781

Enhanced delivery of T cells to tumor after chemotherapy using membrane-anchored, apoptosis-targeted peptide.

Xiaofeng He1, Napolean Bonaparte, Soyoun Kim, Bodhraj Acharya, Ji-Young Lee, Lianhua Chi, Hyoung-Joo Lee, Young-Ki Paik, Pyong-Gon Moon, Moon-Chang Baek, Eun-Kyu Lee, Jong-Ho Kim, In-San Kim, Byung-Heon Lee.   

Abstract

Chemotherapy-induced apoptosis of tumor cells enhances the antigen presentation and sensitizes tumor cells to T cell-mediated cytotoxicity. Here we harnessed the apoptosis of tumor cells as a homing signal for the delivery of T cells to tumor. Jurkat T cells were anchored with ApoPep-1, an apoptosis-targeted peptide ligand, using the biocompatible anchor for membrane (BAM), an oleyl acid derivative. The ApoPep-1-BAM conjugate was efficiently anchored to cell membrane, while little anchoring was obtained with ApoPep-1 alone. The retention period of the ApoPep-1-BAM conjugate on cell membrane was approximately 80 and 40 min in the absence and presence of serum, respectively. ApoPep-1 was resistant to degradation in serum until 2h. The apoptosis-targeted T cells that were anchored with the ApoPep-1-BAM preferentially bound to apoptotic tumor cells over living cells. When intravenously injected into tumor-bearing mice, the number of apoptosis-targeted T cells and in vivo fluorescence signals by the homing of the cells to doxorubicin-treated tumor were higher than those of untargeted T cells. Accumulation of apoptosis-targeted T cells at other organs such as liver was not detected. These results suggest that the chemotherapy-induced apoptosis and subsequent enhancement of T cell delivery to tumor by the membrane anchoring of the apoptosis-targeted peptide could be a novel strategy for cancer immunotherapy.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824781     DOI: 10.1016/j.jconrel.2012.07.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  7 in total

Review 1.  Strategies for cell membrane functionalization.

Authors:  James Pk Armstrong; Adam W Perriman
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

Review 2.  Biomarkers and molecular probes for cell death imaging and targeted therapeutics.

Authors:  Bryan A Smith; Bradley D Smith
Journal:  Bioconjug Chem       Date:  2012-09-26       Impact factor: 4.774

3.  Directing and Potentiating Stem Cell-Mediated Angiogenesis and Tissue Repair by Cell Surface E-Selectin Coating.

Authors:  Zhao-Jun Liu; Pirouz Daftarian; Letícia Kovalski; Bo Wang; Runxia Tian; Diego M Castilla; Emre Dikici; Victor L Perez; Sapna Deo; Sylvia Daunert; Omaida C Velazquez
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

4.  Updated developments on molecular imaging and therapeutic strategies directed against necrosis.

Authors:  Dongjian Zhang; Meng Gao; Qiaomei Jin; Yicheng Ni; Jian Zhang
Journal:  Acta Pharm Sin B       Date:  2019-02-13       Impact factor: 11.413

5.  Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer.

Authors:  Prakash Gangadaran; Gowri Rangaswamy Gunassekaran; Ramya Lakshmi Rajendran; Ji Min Oh; Sri Murugan Poongkavithai Vadevoo; Ho Won Lee; Chae Moon Hong; Byungheon Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Biomedicines       Date:  2022-08-15

6.  Selective recognition of anionic cell membranes using targeted liposomes coated with zinc(ii)-bis(dipicolylamine) affinity units.

Authors:  Serhan Turkyilmaz; Douglas R Rice; Rachael Palumbo; Bradley D Smith
Journal:  Org Biomol Chem       Date:  2014-06-25       Impact factor: 3.876

7.  In vivo near-infrared fluorescence imaging of apoptosis using histone H1-targeting peptide probe after anti-cancer treatment with cisplatin and cetuximab for early decision on tumor response.

Authors:  Hyun-Kyung Jung; Kai Wang; Min Kyu Jung; In-San Kim; Byung-Heon Lee
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.